Menu
Not yet recruiting NCT07502729

Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding

— Observational Portal Hypertension Gastroesophageal Varices Hemorrhage Gastric Varices Esophageal Varices

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Portal Hypertension, Gastroesophageal Varices Hemorrhage, Gastric Varices, Esophageal Varices. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension

Overview

This study aims to evaluate the impact of high-risk factors-such as elevated portal venous pressure, concurrent large extra-luminal vessels, portal vein thrombosis, and prominent portosystemic shunts-on the efficacy of endoscopic therapy. By comparing with interventional treatment, the goal is to optimize the clinical management protocol for esophageal and gastric varices, enhance the therapeutic outcomes of portal hypertension-related esophageal and gastric varices, and improve patient prognosis.

Primary outcome measures

  • 1-year gastrointestinal rebleeding rate [Time frame: 1 year after the treatment.]
Secondary outcome measures (7)
  • 2-month and 6-month gastrointestinal rebleeding rates [Time frame: 2 months and 6 months after the treatment]
  • Indicators in the Child-Pugh classification include the progression of ascites and changes in bilirubin levels. [Time frame: 1, 2, 6, and 12 months after the treatment.]
  • Changes of portal vein thrombosis [Time frame: 6 and 12 months after the treatment.]
  • Liver cancer [Time frame: Up to 12 months after the treatment.]
  • Liver transplantation [Time frame: Up to 12 months after the treatment.]
  • Variceal bleeding-related mortality [Time frame: Up to 12 months after the treatment.]
  • Liver-related mortality [Time frame: Up to 12 months after the treatment.]

Eligibility criteria

Inclusion criteria

  • Admitted due to gastrointestinal bleeding and clinically diagnosed with portal hypertension
  • Underwent imaging examinations and gastroscopy within one week after admission
  • Gastroscopy revealed the presence of esophageal and/or gastric varices
  • Age over 18 years

Exclusion criteria

  • Previous history of liver transplantation
  • Imaging or gastroscopy findings indicated ulcers or other causes of gastrointestinal bleeding
  • Concurrent severe life-threatening diseases involving the circulatory, hematological, or respiratory systems
  • Difficulty in follow-up, or lack of essential medical history information, imaging data, or other necessary records

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07502729 · B2025-835

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗